This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bottini, A. Articles by Berruti, A. Search for Related Content PubMed PubMed Citation Articles by Bottini, A. Articles by Berruti, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Breast Cancer Hazardous Substances DB CYCLOPHOSPHAMIDE Social Bookmarking                            What's this?

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

Alberto Bottini, Daniele Generali, Maria Pia Brizzi, Stephen B. Fox, Alessandra Bersiga, Simone Bonardi, Giovanni Allevi, Sergio Aguggini, Giuliana Bodini, Manuela Milani, Rossana Dionisio, Claudio Bernardi, Arianna Montruccoli, Paolo Bruzzi, Adrian L. Harris, Luigi Dogliotti, Alfredo Berruti

From the Breast Unit and Anatomia Patologica, Azienda Ospedaliera Istituti Ospitalieri Cremona; Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Azienda Ospedaliera San Luigi, Orbassano; Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy; and the John Radcliffe Hospital Oxford, United Kingdom

Address reprint requests to Luigi Dogliotti MD, Oncologia Medica, Azienda Ospedaliera San Luigi, Regione Gondole 10, 10043 Orbassano, Italy; e-mail: luigi.dogliotti{at}unito.it

PURPOSE: To investigate the activity of letrozole plus/minus oral metronomic cyclophophamide as primary systemic treatment (PST) in elderly breast cancer patients.

METHODS: One hundred fourteen consecutive elderly women with T2-4 N0-1 and estrogen receptor–positive breast cancer were randomly assigned to primary letrozole therapy (2.5 mg daily for 6 months) or a combination of letrozole plus oral cyclophosphamide (50 mg/daily for 6 months) in an open-labeled, randomized phase II trial. Tumor response was assessed clinically, and tumor Ki67 index and vascular endothelial growth factor (VEGF) -A levels were measured before and after treatment.

RESULTS: Overall response rate was 71.9% (95% CI, 60.0 to 83.8) in the 57 patients randomly assigned to receive primary letrozole and 87.7% (95% CI, 78.6 to 96.2) in the 57 patients randomly assigned to receive letrozole plus cyclophosphamide. The difference in activity between treatment arms was predominantly confined to patients with ductal histology. There was a significantly greater suppression of Ki67 and VEGF-A expression in the letrozole/cyclophosphamide-treated group than in the letrozole-treated group, leading to lower Ki67 and VEGF expression at post-treatment residual histology (P = .03 and P = .002, respectively).

CONCLUSION: Both letrozole and letrozole plus cyclophosphamide treatments appeared active as PST in elderly breast cancer patients. Metronomic scheduling of cyclophosphamide may have an antiangiogenetic effect and the combination of letrozole plus cyclophosphamide warrants testing in a randomized phase III trial.

Supported in part by the Associazione Patologia Oncologica Mammaria –APOM, Cremona, Italy; the association of Amici dell’ospedale di Cremona; a grant from the Consiglio Nazionale Ricerche, Rome, Italy; Cancer Research UK; and the European Union via the Euroxy Grant.

A.Bo. and D.G. contributed equally to study design and conduct and manuscript preparation.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				E. Briasoulis, P. Pappas, C. Puozzo, C. Tolis, G. Fountzilas, U. Dafni, M. Marselos, and N. Pavlidis Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer Clin. Cancer Res., October 15, 2009; 15(20): 6454 - 6461. [Abstract] [Full Text] [PDF]

				G. Francia, S. Man, C.-J. Lee, C. R. Lee, P. Xu, M. E. Mossoba, U. Emmenegger, J. A. Medin, and R. S. Kerbel Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2-Positive Human Breast Cancer Xenografts Clin. Cancer Res., October 15, 2009; 15(20): 6358 - 6366. [Abstract] [Full Text] [PDF]

				L. G. Daenen, Y. Shaked, S. Man, P. Xu, E. E. Voest, R. M. Hoffman, D. J. Chaplin, and R. S. Kerbel Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models Mol. Cancer Ther., October 1, 2009; 8(10): 2872 - 2881. [Abstract] [Full Text] [PDF]

				D. Generali, G. Bates, A. Berruti, M. P. Brizzi, L. Campo, S. Bonardi, A. Bersiga, G. Allevi, M. Milani, S. Aguggini, et al. Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients Clin. Cancer Res., February 1, 2009; 15(3): 1046 - 1051. [Abstract] [Full Text] [PDF]

				D. Generali, F. M. Buffa, A. Berruti, M. P. Brizzi, L. Campo, S. Bonardi, A. Bersiga, G. Allevi, M. Milani, S. Aguggini, et al. Phosphorylated ER{alpha}, HIF-1{alpha}, and MAPK Signaling As Predictors of Primary Endocrine Treatment Response and Resistance in Patients With Breast Cancer J. Clin. Oncol., January 10, 2009; 27(2): 227 - 234. [Abstract] [Full Text] [PDF]

				D. Generali, S. B. Fox, M. P. Brizzi, G. Allevi, S. Bonardi, S. Aguggini, M. Milani, A. Bersiga, L. Campo, R. Dionisio, et al. Down-Regulation of Phosphatidylinositol 3'-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer Clin. Cancer Res., May 1, 2008; 14(9): 2673 - 2680. [Abstract] [Full Text] [PDF]

				U. Emmenegger, Y. Shaked, S. Man, G. Bocci, I. Spasojevic, G. Francia, A. Kouri, R. Coke, W. Cruz-Munoz, S. M. Ludeman, et al. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice Mol. Cancer Ther., August 1, 2007; 6(8): 2280 - 2289. [Abstract] [Full Text] [PDF]

				K. Narita, J. Chien, S. A. Mullany, J. Staub, X. Qian, W. L. Lingle, and V. Shridhar Loss of HSulf-1 Expression Enhances Autocrine Signaling Mediated by Amphiregulin in Breast Cancer J. Biol. Chem., May 11, 2007; 282(19): 14413 - 14420. [Abstract] [Full Text] [PDF]

				D. Crivellari, M. Aapro, R. Leonard, G. von Minckwitz, E. Brain, A. Goldhirsch, A. Veronesi, and H. Muss Breast Cancer in the Elderly J. Clin. Oncol., May 10, 2007; 25(14): 1882 - 1890. [Abstract] [Full Text] [PDF]